

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/618,977	07/14/2003	Brian L. Bates	PA-5335-RFB	5904	
	7590 01/31/2008 PPATENT OFFICE		EXAM	EXAMINER	
P.O. BOX 2269 BLOOMINGTON, IN 47402			SWEET, THOMAS		
BLOOMINGIO	JN, IN 4/402		ART UNIT	PAPER NUMBER	
			3774		
			MAIL DATE	DELIVERY MODE	
			01/31/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Advisory Action	10/618,977	BATES ET AL.			
* Before the Filing of an Appeal Brief	Examiner	Art Unit			
	Thomas J. Sweet	3774			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence addr	ess		
THE REPLY FILED 18 January 2008 FAILS TO PLACE THIS					
The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expiresmonths from the mailing date of the final rejection.					
b) The period for reply expires on: (1) the mailing date of this Adv event, however, will the statutory period for reply expire later the	The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.				
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).					
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).					
AMENDMENTS					
The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)). The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).					
5. Applicant's reply has overcome the following rejection(s	s): the objection to the declaration.				
6. Newly proposed or amended claim(s) would be a the non-allowable claim(s).	allowable if submitted in a separate	e, timely filed amendm	ent canceling		
For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proposed. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected:	□ will not be entered, or b) □ vovided below or appended.	vill be entered and an	explanation of		
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE					
8. The affidavit or other evidence filed after a final action, because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).	nd sufficient reasons why the affida	ivit or other evidence i	is necessary		
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessary.	overcome <u>all</u> rejections under apperry ry and was not earlier presented.	eal and/or appellant fa See 37 CFR 41.33(d)(ils to provide a (1).		
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER					
11. The request for reconsideration has been considered b See Continuation Sheet.	ut does NOT place the application	in condition for allowa	ince because:		
12. ☐ Note the attached Information Disclosure Statement(s) 13. ☐ Other:	. (PTO/SB/08) Paper No(s).	Thomas Leaving	owed .		
	$\mathcal{N}_{\mathcal{C}}$	was al Exercis	er AUSEL		

Continuation of 11. does NOT place the application in condition for allowance because: In the broadest reasonable interpretation of the claims, both a fluid drug at the surface of a balloon and a coating of drug per se are coating without controlling material. Per se means just that only the drug (independent of other things).